Smith & Nephew gets new indications for hip tech; Life Technologies rolls out new cancer Dx;

Medical Device News

 @FierceMedDev: Abbott Labs is launching its dissolvable coronary stent in Europe, Asia and Latin America. Release | Follow @FierceMedDev

 @MarkHFierce: Bad breath bacteria could be a pancreatic cancer clue. More | Follow @MarkHFierce

 @DamianFierce: Frost & Sullivan says devicemakers must adjust to new pricing pressures to stay afloat. More | Follow @DamianFierce

> Smith & Nephew ($SNN) got 510(k) clearance to expand the indications for two of its hip suture anchors used in hip arthroscopy. News

> Life Technologies ($LIFE) has launched Pervenio Lung RS, a molecular test that can identify early stage lung cancer patients who are at high risk for mortality following surgery. Release

> Despite recent attention to the issue, the software in medical devices is still vulnerable to bugs and hackers, and an IT security expert says the FDA needs to reform its policies to keep patients safe. Article

> Atreca received a $6 million grant from the Bill & Melinda Gates Foundation to use its Immune Repertoire Capture diagnostics platform to discover and develop new vaccines for infectious diseases. More

> After enduring an FDA rejection of its Lymphoseek cancer diagnostic tool this month, Navidea Biopharmaceuticals ($NAVB) says it is working with the FDA to resolve the agency's manufacturing concerns and will refile for approval within 6 months. Item

> Transgenomic has completed its $4.4 million acquisition of Axial Biotech's ScoliScore, a prognostic assay that determines the likelihood of spinal curve progression for patients with an abnormal lateral curve of the spine. Story

> Masimo ($MASI) snagged 510(k) clearance for its Masimo Signal Extraction Technology, or sensors indicated to screen newborns for critical congenital heart disease. More

Biotech News

 @FierceBiotech: In case you missed it last week, check out our 2012 Fierce 15 report: Report | BPA 2012 Slideshow | Follow @FierceBiotech

 @JohnCFierce: One of the two nucs Vertex licensed from Alios ($60M/$1.5B) turned out to be a dud. The other one is headed for PhII. Vertex release | Follow @JohnCFierce

 @RyanMFierce: My interview with Daphne Zohar on how Appeering distills smart banter in biotech from the Twitter hose. Story | Follow @RyanMFierce

> New CEO at GenVec slashes jobs but shelters Novartis partnership. News

> Vertex dumps one hep C dud, races ahead with second all-oral hope. Article

> Is CRO giant Quintiles planning a multibillion-dollar IPO? More

> Sanofi to shed 900 workers with fate of R&D complex undecided. Story

Pharma News

 @FiercePharma: J&J Hid Risks Risperdal Makes Boys' Breasts Grow: Lawyer--Bloomberg. Report | Follow @FiercePharma

> Reckitt to pull Suboxone tabs in favor of on-patent film version. News

> Stada lightens payroll load by 385 with Russian sell-off. More

> French arm-twisting prompts Sanofi to slash job-cuts target. Story

Pharma Manufacturing News

 @EricPFierce: Special report from : 20 Top-selling Vaccines -- H1 2012. Report | Follow @EricPFierce

> Stada sells 2 plants in Russia. News

> Omkar expands its India API production. Article

Biotech Research News

> Roche, AstraZeneca lung cancer Rx beat Alzheimer's in fruit flies and mice. Article

> Constellation gains $7.5M to advance preclinical blood cancer drug. More

> Roswell Park researchers spot versatile cancer treatment. Story

> Natural killer cells may be key to lung cancer susceptibility. Item